Chae, W., Kim, H., & Kim, S
All of our market picks are independently selected and curated by the editorial team
CKD is estimated to develop in ~ 4050% of people with T2D
While millions of Medicare beneficiaries welcome these changes, the federal government is shifting more of the cost of these changes to the Part D drug plan carriers and the pharmaceutical companies
Intranasal delivery of interferon--loaded nanoparticles induces control of neuroinflammation in a preclinical model of multiple sclerosis: a promising simple, effective, non-invasive, and low-cost therapy
Asking the right questions helps patients stay informed, set realistic expectations, and participate actively in their care